Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study -- Company expects to submit New Drug ...

Investors have shown increasing confidence in Eton's market position and its portfolio of products, propelling the stock to unprecedented levels. The surge to an all-time high represents a ...

Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange Book upon the ...

Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce ...

Eton currently has seven commercial rare disease products and four candidates in late-stage development. The FDA has extended the PDUFA goal date for Eton's ET-400 NDA to May 28, 2025, indicating ...

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral ...

– Eton expects to significantly expand patient access to this critical treatment for Wilson disease patients –– $0 co-pay for all eligible patients and best-in-class patient support ...

Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare ...

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ...